F May-Levin

1.6k total citations
43 papers, 1.3k citations indexed

About

F May-Levin is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, F May-Levin has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Genetics and 14 papers in Cancer Research. Recurrent topics in F May-Levin's work include Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (12 papers) and HER2/EGFR in Cancer Research (11 papers). F May-Levin is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (12 papers) and HER2/EGFR in Cancer Research (11 papers). F May-Levin collaborates with scholars based in France, Netherlands and Denmark. F May-Levin's co-authors include H Mouriesse, G Contesso, R. Arriagada, D Sarrazin, F Fontaine, Daniel H. Clarke, Jean‐Paul Travagli, Monique G. Lê, M. Spielmann and J Delarue and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Clinical Epidemiology.

In The Last Decade

F May-Levin

43 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F May-Levin France 18 770 699 430 199 158 43 1.3k
Verena Hug United States 16 767 1.0× 688 1.0× 345 0.8× 234 1.2× 262 1.7× 44 1.4k
Pinuccia Valagussa Italy 10 1.2k 1.6× 1.0k 1.5× 439 1.0× 234 1.2× 208 1.3× 11 1.8k
Robert P. Gray United States 15 718 0.9× 859 1.2× 352 0.8× 197 1.0× 174 1.1× 26 1.3k
Knud Andersen Denmark 18 772 1.0× 1.0k 1.4× 500 1.2× 102 0.5× 241 1.5× 31 1.4k
Ellen R. Gaynor United States 22 751 1.0× 324 0.5× 554 1.3× 199 1.0× 161 1.0× 42 1.6k
Frank J. Cummings United States 14 444 0.6× 480 0.7× 358 0.8× 126 0.6× 146 0.9× 30 1.0k
Susanne Taucher Austria 23 1.1k 1.4× 954 1.4× 456 1.1× 316 1.6× 256 1.6× 45 1.7k
Hans-Joerg Senn Switzerland 13 733 1.0× 649 0.9× 214 0.5× 248 1.2× 359 2.3× 28 1.3k
J Vána United States 10 538 0.7× 709 1.0× 534 1.2× 78 0.4× 146 0.9× 18 1.1k
F J Cummings United States 20 691 0.9× 300 0.4× 215 0.5× 116 0.6× 121 0.8× 35 1.2k

Countries citing papers authored by F May-Levin

Since Specialization
Citations

This map shows the geographic impact of F May-Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F May-Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F May-Levin more than expected).

Fields of papers citing papers by F May-Levin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F May-Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F May-Levin. The network helps show where F May-Levin may publish in the future.

Co-authorship network of co-authors of F May-Levin

This figure shows the co-authorship network connecting the top 25 collaborators of F May-Levin. A scholar is included among the top collaborators of F May-Levin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F May-Levin. F May-Levin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mancini, Julien, Dominique Genre, Florence Dalenc, et al.. (2012). Patients’ regrets after participating in a randomized controlled trial depended on their involvement in the decision making. Journal of Clinical Epidemiology. 65(6). 635–642. 20 indexed citations
2.
Mancini, Julien, Dominique Genre, Florence Dalenc, et al.. (2010). Participants’ uptake of clinical trial results: a randomised experiment. British Journal of Cancer. 102(7). 1081–1084. 15 indexed citations
3.
May-Levin, F, et al.. (2007). Anxiété et cancer de la prostate À propos d’un groupe de parole de patients atteints d’un cancer de la prostate. Psycho-Oncologie. 1(3). 162–168. 6 indexed citations
4.
Terrier, Philippe, et al.. (1996). Use of a Polyclonal Antibody for the Determination of the Prognostic Value of c-erbB-2 Protein Over-Expression in Human Breast Cancer. Acta Oncologica. 35(1). 23–30. 5 indexed citations
5.
Sancho-Garnier, H, J Delarue, H Mouriesse, et al.. (1995). Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product?. European Journal of Cancer. 31(11). 1851–1855. 16 indexed citations
6.
Tyrrell, C., P.F. Bruning, F May-Levin, et al.. (1994). Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Research Explorer (The University of Manchester). 13 indexed citations
7.
Delarue, J, et al.. (1994). Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.. PubMed. 81(12). 1067–77. 12 indexed citations
8.
Toussaint, C., Julie Izzo, M. Spielmann, et al.. (1994). Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.. Journal of Clinical Oncology. 12(10). 2102–2112. 51 indexed citations
9.
10.
Tyrrell, C., P.F. Bruning, F May-Levin, Collette Rose, & J. Ford. (1993). Non comparative multi centre open trial in patients with breast cancer and bone metastases to investigate the effect of apd (pamidronate) on bone healing, morbidity bone metabolism. The Breast. 2(3). 202–203. 1 indexed citations
11.
12.
Arriagada, R., H Mouriesse, M. Spielmann, et al.. (1990). Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. International Journal of Radiation Oncology*Biology*Physics. 19(5). 1207–1210. 21 indexed citations
13.
Lacombe, M. J., J Delarue, H Mouriesse, et al.. (1989). Human breast tumors: A comparison between the biochemical method of measuring estrogen and progesterone receptors and that of an immunohistochemical method. Gynecologic Oncology. 32(2). 174–179. 2 indexed citations
14.
Mouriesse, H, et al.. (1989). A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level.. PubMed. 4(8). 1037–42. 26 indexed citations
15.
Delarue, J, Sam Friedman, H Mouriesse, et al.. (1988). Epidermal growth factor receptor in human breast cancers: Correlation with estrogen and progesterone receptors. Breast Cancer Research and Treatment. 11(2). 173–178. 51 indexed citations
16.
Delarue, J, H Mouriesse, F Dubois, Sam Friedman, & F May-Levin. (1988). Markers in breast cancer: Does CEA add to the detection by CA 15.3?. Breast Cancer Research and Treatment. 11(3). 273–276. 15 indexed citations
17.
Herait, Patrice, P Rougier, J. Oliveira, et al.. (1988). Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer. Investigational New Drugs. 6(4). 323–325. 6 indexed citations
18.
Rouëssé, Jacques, Sam Friedman, D Sarrazin, et al.. (1986). Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.. Journal of Clinical Oncology. 4(12). 1765–1771. 110 indexed citations
19.
May-Levin, F, et al.. (1977). ESTROGEN AND PROGESTOGEN CYTOSOL RECEPTORS IN HUMAN BREAST CARCINOMA. International Journal of Cancer. 19(6). 789–795. 9 indexed citations
20.
May-Levin, F, et al.. (1972). [Utilization of soluble factors produced by lymphocytes as an adjuvant therapeutic method in malignant metastatic tumors. Preliminary results].. PubMed. 102(33). 1188–90. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Verena Hug Breakdown of academic impact, for papers by Pinuccia Valagussa Breakdown of academic impact, for papers by Robert P. Gray Breakdown of academic impact, for papers by Knud Andersen Breakdown of academic impact, for papers by Ellen R. Gaynor Breakdown of academic impact, for papers by Frank J. Cummings Breakdown of academic impact, for papers by Susanne Taucher Breakdown of academic impact, for papers by Hans-Joerg Senn Breakdown of academic impact, for papers by J Vána Breakdown of academic impact, for papers by F J Cummings
Rankless by CCL
2026